The 18 linked references in paper И. Явелов С., И. Явелов С. (2013) “ПЕРОРАЛЬНЫЕ АНТИАГРЕГАНТЫ ПРИ КОРОНАРНОЙ БОЛЕЗНИ СЕРДЦА: ПОЗИЦИИ КЛОПИДОГРЕЛА” / spz:neicon:aterotromboz:y:2013:i:2:p:2-19

  1. 06;354:1706–1717. 2. Wang TH, Bhatt DL, Fox KAA, et al., on behalf of the CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J, 2007; doi:10.1093/eurheartj/ehm274.
  2. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 2008;118:1894–1909.
  3. 1; doi:10.1016/j.jacc.2011.08.007. 20. Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drugeluting stent era: a meta-analysis of randomized trials. Eur Heart J, 2012;33:3078–3087. (the paper at Socionet)
  4. Feres F, Costa RA, Abizaid A, et al.; for the OPTIMIZE Trial Investigators. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents The OPTIMIZE Randomized Trial. JAMA, 2013; doi:10.1001/ jama.2013.282183.
  5. Varenhorst C, Jensevik K, Jernberg T, et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J, 2013; doi:10.1093/eurheartj/eht438.
  6. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med, 2009; doi: 10.1056/NEJMoa0901301. (the paper at Socionet)
  7. Amin AP, Bachuwar A, Reid KJ, et al. Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status. JACC, 2013; doi: 10.1016/j. jacc.2013.02.044.
  8. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC, 2013; 61: doi:10.1016/j.jacc.2012.11.019. (the paper at Socionet)
  9. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012: doi:10.1093/ eurheartj/ehs215.
  10. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J, 2012; doi:10.1093/eurheartj/ehs253.
  11. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2012; doi:10.1093/eurheartj/ehs109.
  12. Mega JL, Braunwald E, Wiviott SD, et al., for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med, 2011; doi: 10.1056/NEJMoa1112277.
  13. Явелов И. С. Антитромботические препараты в профилактике тромбоэмболических осложнений после острого коронарного синдрома. Атеротромбоз, 2013;1:82–104.
  14. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation. JACC, 2013, doi: 10.1016/j.jacc.2013.02.036.
  15. Dewilde WJM, Oirbans T, Verheugt FWA, et al., for the WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; http://–6736 (12)62177–1.
  16. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. JACC, 2013; doi:10.1016/j. jacc.2013.05.029.
  17. Aradi D, Storey RF, Komocsi A, et al., on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J, 2013; doi:10.1093/eurheartj/eht375.
  18. Collet J-P, Cuisset T, Rangé G, et al., for the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med, 2012; DOI: 10.1056/NEJMoa1209979.